InventisBio (SH:688382)2026-02-26 10:30Financial Performance - Total revenue for 2025 is expected to be CNY 37.33 million, a decrease of 77.89% compared to the previous year[3] - The net profit attributable to shareholders of the parent company is projected to be CNY -316.84 million, worsening from CNY -240.20 million in the previous year[3] - The basic earnings per share for 2025 is projected at CNY -0.55, compared to CNY -0.42 in the previous year[3] - The company’s weighted average return on net assets is projected to be -18.91%[3] - The company expects to continue incurring losses in 2025 due to high R&D costs and insufficient revenue from technology licensing and cooperation[7] Assets and Equity - The total assets decreased by 11.29% to CNY 1,703.88 million from CNY 1,920.82 million at the beginning of the period[4] - The equity attributable to shareholders of the parent company fell by 15.17% to CNY 1,536.14 million[4] Research and Development - The company maintained a high level of R&D investment, with ongoing clinical trials for multiple core projects, including D-0502 and D-2570[5] - The company is advancing two innovative preclinical candidates, YF087 and YF550, which show promising anti-tumor potential[6] - The company emphasizes the importance of ongoing R&D and technology platform development for long-term growth[6]